Search results
15 hours ago · SAN MATEO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases with unmet medical needs, today ...
3 hours ago · BJT-778 neutralizes and clears hepatitis B and hepatitis D virions and depletes HBsAg-containing subviral particles, which may help to reconstitute antiviral immunity and contribute to a ...
15 hours ago · ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that two abstracts will be presented as posters ...
15 hours ago · DelveInsight's 'Hepatitis D Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hepatitis D epidemiology in the 7MM, i.e., the United ...
15 hours ago · AIDS (Aussprache [ɛɪ̯t͡s]; Akronym von englisch acquired immune deficiency syndrome „erworbenes Immunschwächesyndrom“, auch „Akquiriertes Immun-Defizienz-Syndrom“) bezeichnet eine spezifische Kombination von Symptomen, die beim Menschen infolge der durch eine HIV-Infektion ausgelösten Zerstörung des Immunsystems auftreten.
15 hours ago · Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D
